Compare BridgeBio Pharma Inc (BBIO) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Old Dominion Freight Line Inc — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Old Dominion Freight Line Inc trades at $233 (market cap $47.55B). The key difference: Old Dominion Freight Line Inc is far larger — about 2.9× BridgeBio Pharma Inc's market cap, and Old Dominion Freight Line Inc pays a 0.51% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | ODFL | |
|---|---|---|
Market Cap | $16.46B | $47.55B |
Sector | Health | Industrials |
52-Week High | $90.17 | $248.73 |
52-Week Low | $44.81 | $126.29 |
Enterprise Value | $18.02B | $47.30B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
ODFL trades at $232.9, up 2.32% today, with a bullish technical signal from moving averages and oscillators. The company maintains strong profitability with an 18.46% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights improving LTL freight demand and a disciplined capital allocation strategy.
Outlook remains positive due to operational strength and market share gains, but elevated valuation multiples and competitive pressures from players like Amazon pose risks. The stock's proximity to its consensus price target of $232.20 suggests limited near-term upside, requiring careful monitoring of Q2 2026 earnings due July 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
